Pharmaust Limited (AU:PAA) has released an update.
PharmAust Limited has successfully secured $10 million through an institutional placement at $0.19 per share, with directors and management contributing $1 million, pending shareholder approval. The funds will support the advancement of the Phase 2/3 STRIKE study for Motor Neurone Disease treatment and other operational activities. Additionally, a Share Purchase Plan (SPP) will be offered to eligible shareholders, allowing them to invest on the same terms as the placement without brokerage fees.
For further insights into AU:PAA stock, check out TipRanks’ Stock Analysis page.
